Compare RNST & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | ARQT |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 1994 | 2020 |
| Metric | RNST | ARQT |
|---|---|---|
| Price | $38.88 | $25.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $42.25 | $32.14 |
| AVG Volume (30 Days) | 699.2K | ★ 1.2M |
| Earning Date | 04-27-2026 | 05-25-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 27.73 | ★ 88.79 |
| EPS | ★ 1.20 | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $31.83 | $26.91 |
| Revenue Next Year | $4.58 | $30.59 |
| P/E Ratio | $31.39 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $27.26 | $11.86 |
| 52 Week High | $42.11 | $31.77 |
| Indicator | RNST | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 42.02 |
| Support Level | $37.45 | $24.81 |
| Resistance Level | $39.91 | $27.26 |
| Average True Range (ATR) | 1.29 | 1.52 |
| MACD | -0.35 | -0.00 |
| Stochastic Oscillator | 42.19 | 7.59 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.